Literature DB >> 11525912

The genotoxic risk of hospital, pharmacy and medical personnel occupationally exposed to cytostatic drugs--evaluation by the micronucleus assay.

H Hessel1, K Radon, A Pethran, B Maisch, S Gröbmair, I Sautter, G Fruhmann.   

Abstract

The aim of this study was to evaluate the genotoxicity of cytostatic drugs in hospital and pharmacy employees (n=100), occupationally exposed. The micronucleus assay was used to study lymphocytes in 247 peripheral blood samples. Samples were collected at "baseline level" without any cytostatic drugs exposure before recruiting or after at least 3 weeks without cytostatic drugs contact and at three times (cycle 1-3) post-exposure. Samples from 60 office employees served as controls. Furthermore, our results were compared to urinary analyses of cytostatic drugs (oxazaphosporines, anthracyclines, platinum) which were collected in parallel to the cytogenetic investigation. Statistical analyses were performed under consideration of age, gender and X-ray exposure. The frequency of micronuclei was significantly related to the age of the subjects (r(Spearman)=0.16; P<0.05). However, there were no significant differences in micronucleus rates between controls and exposed hospital workers. Similarly, micronucleus rates were not significantly different at the various sampling time points and there was no correlation between duration of employment and micronucleus rates. Furthermore, no correlation between current biomonitoring data of exposure (urine tests) and micronuclei frequency was found. Therefore, significantly increased genotoxic damage of the lymphocytes investigated in this study could not be demonstrated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11525912     DOI: 10.1016/s1383-5718(01)00236-4

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

1.  Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: a multicentric approach.

Authors:  Massimo Moretti; Maria Giuseppa Grollino; Sofia Pavanello; Roberta Bonfiglioli; Milena Villarini; Massimo Appolloni; Mariella Carrieri; Laura Sabatini; Luca Dominici; Laura Stronati; Giuseppe Mastrangelo; Anna Barbieri; Cristina Fatigoni; Giovanni Battista Bartolucci; Elisabetta Ceretti; Francesca Mussi; Silvano Monarca
Journal:  Int Arch Occup Environ Health       Date:  2014-11-02       Impact factor: 3.015

2.  Genotoxic evaluation of occupational exposure to antineoplastic drugs.

Authors:  Andres Felipe Aristizabal-Pachon; Willian Orlando Castillo
Journal:  Toxicol Res       Date:  2019-12-02

3.  Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs.

Authors:  Cinzia Lucia Ursini; Delia Cavallo; Antonio Colombi; Margherita Giglio; Alessandro Marinaccio; Sergio Iavicoli
Journal:  Int Arch Occup Environ Health       Date:  2006-06-08       Impact factor: 3.015

4.  Biomonitoring results and cytogenetic markers among harbour workers with potential exposure to river silt aerosols.

Authors:  R Wegner; K Radon; R Heinrich-Ramm; B Seemann; A Riess; F Koops; B Poschadel; D Szadkowski
Journal:  Occup Environ Med       Date:  2004-03       Impact factor: 4.402

5.  A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project.

Authors:  Massimo Moretti; Roberta Bonfiglioli; Donatella Feretti; Sofia Pavanello; Francesca Mussi; Maria G Grollino; Milena Villarini; Anna Barbieri; Elisabetta Ceretti; Mariella Carrieri; Annamaria Buschini; Massimo Appolloni; Luca Dominici; Laura Sabatini; Umberto Gelatti; Giovanni B Bartolucci; Paola Poli; Laura Stronati; Giuseppe Mastrangelo; Silvano Monarca
Journal:  BMC Public Health       Date:  2011-03-30       Impact factor: 3.295

6.  Toxicological assessment of noxious inhalants.

Authors:  N H Kleinsasser; A W Sassen; B W Wallner; R Staudenmaier; U A Harréus; E Richter
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.